Back to top
more

Taro Pharmaceutical Industries (TARO)

(Delayed Data from NYSE)

$42.23 USD

42.23
22,565

-0.03 (-0.07%)

Updated Apr 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

by Zacks Equity Research

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Procaps Group, S.A. (PROC) delivered earnings and revenue surprises of 60% and 7.26%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

by Zacks Equity Research

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

by Zacks Equity Research

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

by Zacks Equity Research

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Taro (TARO) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Taro (TARO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

All You Need to Know About Taro (TARO) Rating Upgrade to Strong Buy

by Zacks Equity Research

Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro (TARO) Surges 6.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Taro Pharmaceutical (TARO) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -35.29% and -13.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.